High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer's marketing ...

This growth guidance considers the reduction of sales associated with the previously announced global withdrawal of Oxbryta. Pfizer Expects 2024 adjusted EPS of $2.75-$2.95 compared to prior ...

Eliquis' slowing year-on-year sales growth rate, as well as the withdrawal of Oxbryta from the market, are additional risks that, in my opinion, will continue to have a negative impact on Pfizer's ...

In September, Pfizer withdrew Oxbryta (voxelotor) for sickle cell disease, added via its $5.4 billion buyout of Global Blood Therapeutics in 2022. Starboard contended that Pfizer overpaid for its ...

When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...

A drug projected to have over $3B peak sales potential, Oxbryta was added to Pfizer's (PFE) portfolio following its $5B acquisition of Global Blood Therapeutics in 2022. "For large pharma ...

and pulling its sickle cell disease treatment Oxbryta due to deaths in its clinical trials. Smith did not make any specific prescriptions for Pfizer or its management at the presentation.

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ...